Display options
Cite
Thomas BF, Pollard GT. Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States. Front Pharmacol. 2016;7:285doi: 10.3389/fphar.2016.00285.
Thomas, B. F., & Pollard, G. T. (2016). Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States. Frontiers in pharmacology, 7285. https://doi.org/10.3389/fphar.2016.00285
Thomas, Brian F, and Pollard, Gerald T. "Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States." Frontiers in pharmacology vol. 7 (2016): 285. doi: https://doi.org/10.3389/fphar.2016.00285
Thomas BF, Pollard GT. Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States. Front Pharmacol. 2016 Aug 31;7:285. doi: 10.3389/fphar.2016.00285. eCollection 2016. PMID: 27630566; PMCID: PMC5006560.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2016 Aug 31;7:285. doi: 10.3389/fphar.2016.00285. eCollection 2016.

Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States.

Frontiers in pharmacology

Brian F Thomas, Gerald T Pollard

Affiliations

  1. Discovery Sciences, Research Triangle Institute, Research Triangle Park Durham, NC, USA.
  2. Howard Associates, LLC, Research Triangle Park Durham, NC, USA.

PMID: 27630566 PMCID: PMC5006560 DOI: 10.3389/fphar.2016.00285

Abstract

Cannabis is classified as a schedule I controlled substance by the US Drug Enforcement Agency, meaning that it has no medicinal value. Production is legally restricted to a single supplier at the University of Mississippi, and distribution to researchers is tightly controlled. However, a majority of the population is estimated to believe that cannabis has legitimate medical or recreational value, numerous states have legalized or decriminalized possession to some degree, and the federal government does not strictly enforce its law and is considering rescheduling. The explosive increase in open sale and use of herbal cannabis and its products has occurred with widely variable and in many cases grossly inadequate quality control at all levels-growing, processing, storage, distribution, and use. This paper discusses elements of the analytical and regulatory system that need to be put in place to ensure standardization for the researcher and to reduce the hazards of contamination, overdosing, and underdosing for the end-user.

Keywords: DEA controlled substances; cannabidiol; cannabinoids; cannabis; marijuana; quality control; therapeutics; Δ9-tetrahydrocannabinol (Δ9-THC)

References

  1. JAMA. 2015 Jun 23-30;313(24):2491-3 - PubMed
  2. Science. 2016 Jun 3;352(6290):1182 - PubMed
  3. Nature. 2015 Mar 19;519(7543):269-70 - PubMed
  4. Bioscience. 2015 Aug 1;65(8):822-829 - PubMed
  5. Clin Pharmacol Ther. 1973 Jan-Feb;14(1):48-55 - PubMed
  6. Biol Psychiatry. 2016 Apr 1;79(7):613-9 - PubMed
  7. J Toxicol Sci. 2015 Dec;40(6):797-803 - PubMed
  8. Addiction. 2008 Oct;103(10):1671-7 - PubMed
  9. Regul Toxicol Pharmacol. 2014 Aug;69(3):284-8 - PubMed
  10. Nature. 2014 Mar 27;507(7493):407-8 - PubMed
  11. J Am Vet Med Assoc. 2014 Oct 1;245(7):726-8 - PubMed

Publication Types

Grant support